People · Operator
Named in public records as an officer, director or promoter · active 2019–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Frontier Medicines Corp | — | Biotechnology | Series C | $122.0M | $2.5B | 2019 |
| Cyteir Therapeutics, Inc. | — | Biotechnology | Series C | $111.9M | $2.6B | 2019 |
| AmbAgon Therapeutics Inc. | — | Biotechnology | Series C | $55.4M | $35.9M | 2020 |
Janwillem Naesens at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Janwillem Naesens on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Luke Evnin | 1 | 12 |
| Cameron Wheeler | 1 | 9 |
| JOSEPH S. ZAKRZEWSKI | 1 | 6 |
| Jean George | 1 | 6 |
| Adam Rosenberg | 1 | 6 |
| Margarita Chavez | 1 | 4 |
| Kevin Mills | 1 | 4 |
| Karen Hong | 1 | 4 |
| Peter Dudek | 1 | 2 |
| Othman Laraki | 1 | 2 |
| Barry Mills | 1 | 2 |
| William B. Asher, Jr. | 1 | 1 |
| Melissa McCracken | 1 | 1 |
| Josh Seidenfeld | 1 | 1 |
| Christian Ottmann | 1 | 1 |
| Michelle Arkin | 1 | 1 |
| Roel Bulthuis | 1 | 1 |
| Nancy Pryer | 1 | 1 |
| Bryan Miller | 1 | 1 |
| Scott Clarke | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.